World Vaccine Congress Europe 2026 has ended. This guide stays up as the record of who was there. Next: WVC Europe 2027, Oct 25–27, 2027 in Lyon
Public-health bodies and non-profits at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
45 public-health bodies and non-profits are at World Vaccine Congress Europe 2026 — 91 presentations on the program and 4 with a booth in the exhibit hall. Most represented: IAVI (5 on the program), PATH (5 on the program), European Medicines Agency (4 on the program). 21 of them have their own page in this guide. As of Oct 12, 2026.
All 268 organizations at World Vaccine Congress Europe 2026 →
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
IAVI New York, NY | |
Non-profit research organization developing vaccines and antibodies for HIV, tuberculosis and emerging infectious diseases. | Talk Mon Oct 19 11:30 Talk Mon Oct 19 11:45 Panel Mon Oct 19 12:15 Session Wed Oct 21 10:30 Session Wed Oct 21 12:15 Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. |
PATH Seattle, WA | |
Global health non-profit working on vaccine development, delivery and immunization systems in low- and middle-income countries. | Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. Talk Mon Oct 19 16:30 Talk Mon Oct 19 16:45 Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. Infectious disease & AMR Talk Wed Oct 21 12:00 Working Group: The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used? How a new framework ranks which combination vaccines for children matter most, and how to get those vaccines developed, approved and used. Supply, safety & access Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. |
European Medicines Agency Amsterdam, Netherlands | |
The European Union's medicines regulator, evaluating and monitoring vaccines and medicines. | Panel Mon Oct 19 12:15 Panel: Chronic Conditions and Off-target Effects of Vaccines Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it. Panel Mon Oct 19 14:15 Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery Why common doubts about needle-free vaccine delivery, such as cost, regulation and patient uptake, may no longer hold up. Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:00 Working Group: Quality Communication for Vaccine Literacy and Uptake Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions. Supply, safety & access Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
CEPI Oslo, Norway | |
Coalition for Epidemic Preparedness Innovations: global partnership funding vaccines against emerging infectious diseases and epidemic threats. | Panel Mon Oct 19 12:15 Talk Tue Oct 20 16:00 Panel: Expanding the Access & Impact of Adjuvants How to get past licensing and approval hurdles so new adjuvants, ingredients that boost a vaccine's immune response, reach more countries. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. Talk Wed Oct 21 15:15 Panel Wed Oct 21 16:00 Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems How Europe can shift vaccine funding from crisis-driven spending to long-term plans, using tools like joint purchasing and advance promises to buy. Supply, safety & access |
European Commission Brussels, Belgium | |
Executive body of the European Union, setting EU health, health-security and veterinary policy. | Talk Wed Oct 21 09:00 The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World How governments and industry can keep vaccines flowing fairly across borders in an emergency as countries push to make vaccines at home. Supply, safety & accessBioprocess & manufacturing Talk Wed Oct 21 10:45 Panel Wed Oct 21 11:00 Panel: Rethinking Livestock Vaccination for Emerging Threats How to speed new livestock vaccines against diseases that can jump to people, weighing approval rules, food safety, trade and funding incentives. Panel Wed Oct 21 16:00 Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems How Europe can shift vaccine funding from crisis-driven spending to long-term plans, using tools like joint purchasing and advance promises to buy. Supply, safety & access |
African Field Epidemiology Network (AFENET) Kampala, Uganda | |
Non-profit network that trains field epidemiologists and supports disease surveillance, outbreak response and immunization programs across Africa. | Booth Exhibiting (no floor booth listed) Talk Mon Oct 19 15:45 Talk Tue Oct 20 11:30 |
World Health Organization (WHO) Geneva, Switzerland | |
UN health agency that sets vaccine policy, prequalifies vaccines and guides research and development priorities. | Talk Mon Oct 19 14:15 Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. Infectious disease & AMR Talk Tue Oct 20 11:30 Working Group: Partnerships for Prevention: Accelerating Vaccines to Curb Antimicrobial Resistance How partnerships across sectors could speed up and widen access to vaccines against drug-resistant bacteria, such as a maternal Klebsiella vaccine for newborns. Infectious disease & AMRSupply, safety & access Talk Wed Oct 21 12:00 Working Group: The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used? How a new framework ranks which combination vaccines for children matter most, and how to get those vaccines developed, approved and used. Supply, safety & access Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. |
International Vaccine Institute Seoul, South Korea | |
International non-profit organization developing and delivering vaccines for global health. | Talk Mon Oct 19 14:15 Panel: Preparing for Disease X: Approaches for the Next Spillover How to spot the next unknown disease jumping from animals to people early, and how vaccines could be readied or stockpiled beforehand. Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:15 Panel: The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs Why low- and middle-income countries are becoming vaccine innovators, not just trial sites, and what funding and regional regulatory cooperation they need. Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. |
Find buyers from public-health bodies and non-profits
Tell us what you sell and we’ll find the people at these public-health bodies and non-profits most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse World Vaccine Congress Europe 2026 by
Not affiliated with or endorsed by the World Vaccine Congress or its organizers. Submit a correction